Olaparib (trade name Lynparza) is a PARP inhibitor for the treatment of germline BRCA mutated (gBRCAm) advanced ovarian cancer that has received three or more prior lines of chemotherapy. Olaparib has been approved by the U.S Food and Drug Administration on December 19, 2014.
Product Name: Olaparib
CAS Number: 763113-22-0
Molecular Weight:  434.4691
Molecular Formula:  C24H23FN4O3
Purity (HPLC): ≥99%
Shipping Conditions: Room temperature.
Storage Conditions: Refrigerated.
Regulatory Statement:  For Research Use Only.